About 2'-5'-oligoadenylate synthase 1
2'-5'-oligoadenylate synthase 1 (OAS1) is a protein
from Homo sapiens identified by UniProt accession
P00973, 400 residues long.
MolForge cross-references it against 0 known binders and
233 disease associations.
Target properties
| Protein name | 2'-5'-oligoadenylate synthase 1 |
| UniProt accession | P00973 |
| Gene | OAS1 |
| Organism | Homo sapiens |
| Length | 400 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (233)
Diseases linked to this target (Open Targets).
- pulmonary alveolar proteinosis with hypogammaglobulinemia · score 0.60
- COVID-19 · score 0.37
- neurodegenerative disease · score 0.32
- urate measurement · score 0.26
- systemic lupus erythematosus · score 0.22
- serum gamma-glutamyl transferase measurement · score 0.22
- hypertension · score 0.20
- type 2 diabetes mellitus · score 0.20
- chronic lymphocytic leukemia · score 0.19
- thyroid gland adenocarcinoma · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P00973-F1 | alphafold | PREDICTED | 83.91 | — |
Amino-acid sequence (400 residues)
MMDLRNTPAK SLDKFIEDYL LPDTCFRMQI NHAIDIICGF LKERCFRGSS YPVCVSKVVK GGSSGKGTTL RGRSDADLVV FLSPLTTFQD QLNRRGEFIQ EIRRQLEACQ RERAFSVKFE VQAPRWGNPR ALSFVLSSLQ LGEGVEFDVL PAFDALGQLT GGYKPNPQIY VKLIEECTDL QKEGEFSTCF TELQRDFLKQ RPTKLKSLIR LVKHWYQNCK KKLGKLPPQY ALELLTVYAW ERGSMKTHFN TAQGFRTVLE LVINYQQLCI YWTKYYDFKN PIIEKYLRRQ LTKPRPVILD PADPTGNLGG GDPKGWRQLA QEAEAWLNYP CFKNWDGSPV SSWILLAESN SADDETDDPR RYQKYGYIGT HEYPHFSHRP STLQAASTPQ AEEDWTCTIL
Explore 2'-5'-oligoadenylate synthase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets